By: David McNewThe US government is quietly selling hydrocortizone to doctors without testing them, and is using this new tool to cover up its misdeeds.
The US Food and Drug Administration (FDA) approved the drug on December 2, 2017, with the intent to make it easier to prescribe for depression, according to documents seen by the New York Times.
But when it came to prescribing it, doctors weren’t given a single opportunity to discuss its side effects and the potential harms it could pose.
The drug, also known as fluoxetine, is used to treat depression and anxiety.
The FDA allowed its approval to be withdrawn for a few months in 2019, but did not allow it to be sold to the general public until November of 2021, the next year.
The decision was made because the FDA could not find adequate research on the drug and lacked the expertise to review and evaluate the data on its safety.
It was made clear that the FDA would only authorize prescribing the drug for people who have depression, panic disorder, bipolar disorder, or other mental health conditions that might require a medication.
The FDA was required to review all studies and data that would support its approval and make a decision based on that.
However, in a move that is completely unprecedented, the FDA is now selling hydrogel to doctors for use in treating depression without testing.
It is not clear why doctors are not being told about the potential side effects, but one theory is that the company is afraid of having the drug prescribed to people who might not have the same issues.
A recent study found that hydrocontramide is associated with an increased risk of suicide.
Dr. Peter Kavulich, the lead author of the study, said that he was concerned that the government was trying to avoid taking the risk of making depression available to patients who need it, by only prescribing it to people with depression.
“We can’t be in this business to get it for everybody, and I think it’s the wrong approach,” he said.
It is unclear how many doctors have taken the drug, but according to the Times, a representative of the company did not respond to requests for comment.
Many of the doctors who have been prescribing the medication without testing are not taking the drug as directed.
On January 5, 2017 and again on February 4, the same day, the manufacturer, New York-based MediPharm, announced that it was removing hydrocourtisone from its prescription drug list.
According to the FDA’s website, the drug is used for the treatment of depression, anxiety, panic attacks, bipolar, obsessive-compulsive, and other mental illnesses.
In response to the news, Dr. John S. Bortolotti, director of the Office of Therapeutic Goods Administration’s Center for Medicinal Products and the Drug Administration, wrote in a statement: The Centers for Medicare and Medicaid Services (CMS) has reviewed the data, clinical trial data, and data from independent and third-party organizations on the safety and effectiveness of the drug hydrocoronitraconitr, and has determined that it is safe and efficacious.
Hydrocorofortely is the first antidepressant to be approved by the FDA to treat a serious depressive disorder, which includes bipolar disorder.
Hydroxychlorothioate, which is in the hydrococoronidinone (HC-OH) formulation, has also been approved for the treating of panic disorder and panic disorder with generalized anxiety disorder.
This story has been updated to include the name of the hydrogels manufacturer, the name and location of the pharmacy where the drug was purchased, and a statement from the FDA.